Partial clinical hold placed on Alnylam, Regeneron RNAi Alzheimer's candidate. The US FDA has placed a partial clinical hold on Alnylam Pharmaceuticals (NASDAQ:ALNY) and Regeneron Pharmaceuticals' (REGN) RNAi candidate ALN-APP, under investigation for Alzheimer's disease and cerebral amyloid angiopathy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.